These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 36516090

  • 1. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP.
    N Engl J Med; 2022 Dec 15; 387(24):2211-2219. PubMed ID: 36516090
    [Abstract] [Full Text] [Related]

  • 2. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
    Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O'Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP.
    Nat Med; 2022 Apr 15; 28(4):780-788. PubMed ID: 35347281
    [Abstract] [Full Text] [Related]

  • 3. Beremagene Geperpavec: First Approval.
    Dhillon S.
    Drugs; 2023 Aug 15; 83(12):1131-1135. PubMed ID: 37432558
    [Abstract] [Full Text] [Related]

  • 4. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
    Paller AS, Guide SV, Ayala D, Gonzalez ME, Lucky AW, Bagci IS, Marinkovich MP.
    J Dermatolog Treat; 2024 Dec 15; 35(1):2350232. PubMed ID: 38724041
    [Abstract] [Full Text] [Related]

  • 5. Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
    Tovar Vetencourt A, Sayed-Ahmed I, Gomez J, Chen H, Agostini B, Carroll K, Parry T, Krishnan S, Sabater AL.
    N Engl J Med; 2024 Feb 08; 390(6):530-535. PubMed ID: 38324486
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M.
    J Clin Invest; 2017 Aug 01; 127(8):3028-3038. PubMed ID: 28691931
    [Abstract] [Full Text] [Related]

  • 8. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP.
    JAMA; 2016 Nov 01; 316(17):1808-1817. PubMed ID: 27802546
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.
    Raymakers AJN, Kesselheim AS, Mostaghimi A, Feldman WB.
    JAMA Dermatol; 2024 Mar 01; 160(3):297-302. PubMed ID: 38294784
    [Abstract] [Full Text] [Related]

  • 13. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
    Epstein AL, Haag-Molkenteller C.
    Cell; 2023 Aug 17; 186(17):3523-3523.e1. PubMed ID: 37595560
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa.
    Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, Kiritsi D, McGrath JA, Tolar J, Frank MH, Kluth MA.
    Cytotherapy; 2023 Jul 17; 25(7):782-788. PubMed ID: 36868990
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa.
    Solis DC, Gorell ES, Teng C, Barriga M, Nazaroff J, Li S, Subica A, Lu Y, Marinkovich MP, Tang JY.
    Pediatr Dermatol; 2021 May 17; 38(3):704-706. PubMed ID: 33749033
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
    Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J.
    N Engl J Med; 2010 Aug 12; 363(7):629-39. PubMed ID: 20818854
    [Abstract] [Full Text] [Related]

  • 19. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A.
    J Invest Dermatol; 2021 Apr 12; 141(4):883-893.e6. PubMed ID: 32946877
    [Abstract] [Full Text] [Related]

  • 20. Restoring type VII collagen in skin.
    Lwin SM, McGrath JA.
    Med; 2022 May 13; 3(5):273-275. PubMed ID: 35584643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.